Table 1. Australian clinical guidelines for endocrine therapy use in women with hormone-dependent early breast cancer [12], [13].

Menopause status	Treatment guidelines
Pre-menopausal	Tamoxifen only
Post-menopausal	Choice of endocrine therapy based on risk of recurrence
	High risk (tumours >2 cm)
	• Endocrine therapy should commence with an aromatase inhibitor
	Intermediate risk (tumours 1.1–2 cm)
	• Adjuvant endocrine therapy with an aromatase inhibitor is recommended
	Low risk (tumours ≤1 cm)
	• Treatment with tamoxifen is recommended rather than with an aromatase inhibitor as the balance between benefits and harms of aromatase inhibitor is unclear for such women